Platinum Membership for 'International Consortium for Clinical Data Standards (CDISC)'
JNPMEDI, a medical data platform company, acquires a platinum membership of the "Clinical Data Interchange Standard Consortium (CDISC)." JNPMEDI's acquisition of the CDISC Platinum membership means that it guarantees that it can provide customers with clinical trial results that meet international standards by operating clinical trials based on CDISC standards.
JNPMEDI acquires a platinum membership of the "Clinical Data Interchange Standard Consortium (CDISC)." CDISC is an international non-profit organization that defines the standard format of clinical trial data. Regulators in each country, including the U.S. FDA, European EMA, and Japan's PMDA, are implementing new drug, medical devices, and medical technology approval procedures by mandating the application of CDISC's standard format. Accordingly, global pharmaceutical companies and research institutes are submitting clinical trial data to regulators in accordance with CDISC standards.
JNPMEDI's acquisition of the CDISC Platinum membership means that it guarantees that it can provide customers with clinical trial results that meet international standards by operating clinical trials based on CDISC standards. As a result, customers using JNPMEDI's "Maven Clinical Cloud" can manage data by applying international standards at a reasonable cost.
Maven Clinical Cloud is a SaaS-based solution that can be used by selecting only the necessary services, enabling more efficient clinical trial data management and analysis based on CDISC international clinical data standards.
Meanwhile, JNPMEDI plans to participate as a platinum member in CDISC Interchange events in Korea, the United States, Europe, and Japan, and it plans to attend the 2023 US Interchange in October this year as a single booth to showcase its solutions to global customers.